全球消化器官系統治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

預計到 2034 年，消化器官系統藥物市場規模將達到 651.5 億美元，而 2025 年為 468.5 億美元，預計 2026 年至 2034 年的複合年成長率將達到 3.73%。

由於全球胃腸道疾病發生率不斷上升，全球胃腸道治療市場正顯著成長。諸如大腸激躁症、發炎性腸道疾病和胃食道逆流等疾病日益常見，推動了對有效治療方法的需求。飲食習慣的改變、久坐的生活方式以及壓力水平的增加是導致胃腸道疾病發病率上升的主要因素。因此，醫療專業人員正致力於改善治療效果和患者照護。

醫藥技術的進步和創新治療方法的研發在市場成長中發揮著至關重要的作用。生物製藥、標靶治療和新型製劑正在提高消化器官系統疾病的治療效果。此外，製藥公司活性化研發投入，推動了新型和改良藥物的上市。醫療基礎設施的不斷改進和人們對胃腸道健康意識的提高也為市場擴張提供了支持。

未來幾年，在持續的醫學研究和不斷成長的醫療保健投資的推動下，消化器官系統藥物市場預計將繼續成長。對個人化醫療和標靶治療的日益重視將進一步改善治療效果。此外，老年人口的不斷成長以及易患消化器官系統疾病的人群數量增加，也將繼續支撐對先進療法的需求。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球消化器官系統治療市場：按類型分類

• 市場分析、洞察與預測
• 品牌商品
• 學名藥

第5章 全球消化器官系統治療藥物市場：依藥物類別分類

• 市場分析、洞察與預測
• 氨基水楊酸類藥物
• 消化酵素
• 質子幫浦阻斷劑
• 瀉藥
• 止吐藥
• H2受體拮抗劑
• 止瀉
• 生物製藥/生物相似藥
• 其他

第6章：全球消化器官系統治療藥物市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射藥物
• 其他

第7章 全球消化器官系統治療市場：依應用分類

• 市場分析、洞察與預測
• 克隆氏症
• 潰瘍性大腸炎
• GERD
• IBS
• 其他

第8章 全球消化器官系統治療藥物市場：按分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第9章 全球消化器官系統治療市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • AstraZeneca
  • Janssen Pharmaceuticals NV
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Salix Pharmaceuticals
  • Pfizer Inc
  • Bayer AG
  • Abbott
  • Cipla Inc
  • Gilead Sciences Inc
  • Biogen
  • Organon Group

The Gastrointestinal Therapeutics Market size is expected to reach USD 65.15 Billion in 2034 from USD 46.85 Billion (2025) growing at a CAGR of 3.73% during 2026-2034.

The global gastrointestinal therapeutics market is growing significantly due to the rising prevalence of digestive disorders worldwide. Conditions such as irritable bowel syndrome, inflammatory bowel disease, and gastroesophageal reflux disease are becoming increasingly common, driving demand for effective treatment options. Changing dietary habits, sedentary lifestyles, and increasing stress levels are major factors contributing to the growing incidence of gastrointestinal disorders. As a result, healthcare providers are focusing on improving treatment outcomes and patient care.

Pharmaceutical advancements and the development of innovative therapies are playing a crucial role in market growth. Biologics, targeted therapies, and novel drug formulations are improving the effectiveness of gastrointestinal treatments. Additionally, increased research and development activities by pharmaceutical companies are leading to the introduction of new and improved medications. The expansion of healthcare infrastructure and growing awareness about digestive health are also supporting market expansion.

In the coming years, the gastrointestinal therapeutics market is expected to witness continued growth driven by ongoing medical research and increasing healthcare investments. The rising focus on personalized medicine and targeted therapies will further enhance treatment outcomes. Moreover, the growing aging population, which is more susceptible to gastrointestinal disorders, will continue to support demand for advanced therapeutics.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Branded
• Generics

By Drug Class

• Aminosalicylates
• Digestive enzymes
• Proton Pump Inhibitors
• Laxatives
• Anti-Emetics
• H2 Antagonists
• Anti-Diarrheal
• Biologics/Biosimilar
• Others

By Route of Administration

• Oral
• Injectable
• Others

By Application

• Crohn's disease
• Ulcerative colitis
• GERD
• IBS
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, AstraZeneca, Janssen Pharmaceuticals NV, Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals, Pfizer Inc, Bayer AG, Abbott, Cipla Inc, Gilead Sciences Inc, Biogen, Organon Group
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Drug Class
• 5.2. Aminosalicylates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Digestive enzymes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Proton Pump Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Laxatives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Anti-Emetics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. H2 Antagonists Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Anti-Diarrheal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Biologics/Biosimilar Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Crohn's disease Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Ulcerative colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. GERD Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. IBS Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL GASTROINTESTINAL THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Type
  • 9.2.2 By Drug Class
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Application
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Type
  • 9.3.2 By Drug Class
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Application
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Type
  • 9.4.2 By Drug Class
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Application
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Type
  • 9.5.2 By Drug Class
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Application
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Type
  • 9.6.2 By Drug Class
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Application
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL GASTROINTESTINAL THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 AbbVie Inc
  • 11.2.2 AstraZeneca
  • 11.2.3 Janssen Pharmaceuticals NV
  • 11.2.4 Sun Pharmaceutical Industries Ltd
  • 11.2.5 Takeda Pharmaceutical Company Limited
  • 11.2.6 Salix Pharmaceuticals
  • 11.2.7 Pfizer Inc
  • 11.2.8 Bayer AG
  • 11.2.9 Abbott
  • 11.2.10 Cipla Inc
  • 11.2.11 Gilead Sciences Inc
  • 11.2.12 Biogen
  • 11.2.13 Organon Group